CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2018-12-30
2017-12-30
2016-12-30
Total Revenue
1,653
2,428
2,045
589
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
37,014
24,479
9,233
5,100
Selling General and Administrative
12,688
6,659
1,939
1,533
Total Operating Expenses
49,702
31,138
11,172
6,633
Operating Income or Loss
-48,049
-28,710
-9,127
-6,044
Interest Expense
-
0
8
11
Total Other Income/Expenses Net
-123
-153
-48
-1
Income Before Tax
-44,368
-27,115
-9,157
-6,019
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-44,368
-27,115
-9,157
-6,019
Net Income
-44,368
-27,115
-9,157
-6,019
Net Income available to common shareholders
-44,368
-27,115
-9,157
-6,019
Reported EPS
Basic
-
-2.23
-1.18
-0.43
Diluted
-
-2.23
-1.18
-0.43
Weighted average shares outstanding
Basic
-
12,142
7,746
13,878
Diluted
-
12,142
7,746
13,878
EBITDA
-
-26,644
-9,021
-5,916